IMMUNOPRECISE ANTIBOD.
MindWalk operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its na… Read more
Market Cap & Net Worth: IMMUNOPRECISE ANTIBOD. (TQB)
IMMUNOPRECISE ANTIBOD. (F:TQB) has a market capitalization of $74.64 Million (€72.71 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #19831 globally and #2115 in its home market, demonstrating a -26.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IMMUNOPRECISE ANTIBOD.'s stock price €1.58 by its total outstanding shares 46154100 (46.15 Million).
IMMUNOPRECISE ANTIBOD. Market Cap History: 2017 to 2025
IMMUNOPRECISE ANTIBOD.'s market capitalization history from 2017 to 2025. Data shows change from $68.70 Million to $74.64 Million (-10.67% CAGR).
IMMUNOPRECISE ANTIBOD. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IMMUNOPRECISE ANTIBOD.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TQB by Market Capitalization
Companies near IMMUNOPRECISE ANTIBOD. in the global market cap rankings as of March 19, 2026.
Key companies related to IMMUNOPRECISE ANTIBOD. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
IMMUNOPRECISE ANTIBOD. Historical Marketcap From 2017 to 2025
Between 2017 and today, IMMUNOPRECISE ANTIBOD.'s market cap moved from $68.70 Million to $ 74.64 Million, with a yearly change of -10.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €74.64 Million | +301.89% |
| 2024 | €18.57 Million | -73.87% |
| 2023 | €71.06 Million | -68.84% |
| 2022 | €228.07 Million | +1.99% |
| 2021 | €223.61 Million | -68.95% |
| 2020 | €720.11 Million | +695.81% |
| 2019 | €90.49 Million | -19.75% |
| 2018 | €112.75 Million | +64.14% |
| 2017 | €68.70 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of IMMUNOPRECISE ANTIBOD. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $74.64 Million USD |
| MoneyControl | $74.64 Million USD |
| MarketWatch | $74.64 Million USD |
| marketcap.company | $74.64 Million USD |
| Reuters | $74.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.